Corbus Pharmaceuticals announced Phase 1b CANYON-1 data for CRB-913, achieving 5.0% mean weight loss at 12 weeks with no plateau. Due to strict peripheral restriction (0% brain penetration), the oral β¦
π Strict Peripheral Restriction: Binds CB1 in liver and fat deposits while completely barred from crossing the blood-brain barrier.
π₯ Hepatic Clearance: Produces a 42% relative reduction in hepatic steatosis alongside significant glycemic improvements.
Compound Class: Peripherally restricted CB1 inverse agonist
Mean Weight Loss: 5.0% at 12 weeks (60 mg cohort)
CNS Penetration: Negative (< 0.01 brain/plasma ratio)
Administration: Oral capsule once daily
Corbus Pharmaceuticals announced Phase 1b CANYON-1 data for CRB-913, achieving 5.0% mean weight loss at 12 weeks with no plateau. Due to strict peripheral restriction (0% brain penetration), the oral CB1 inverse agonist caused zero psychiatric adverse events.
Offers a daily oral tablet driving metabolic lipid burning without gastrointestinal paralysis or muscle sarcopenia.
Regulatory frameworks and infrastructure readiness remain critical.
By 2028, oral peripherally restricted CB1 inverse agonists will challenge injectable GLP-1 dominance in cardiometabolic disease.